Danish Evaxion Biotech has dosed the first patient in a clinical phase I trial targeting three forms of cancer. The company develops personalized cancer immunotherapies via its artificial intelligence platform, and the market is worth millions of dollars, says the CEO.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.